Cargando…
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients
BACKGROUND: We previously reported an HLA-A24-restricted cytotoxic T-cell epitope, Survivin-2B80-88, derived from a splice variant of survivin, survivin-2B. In this report, we show a novel HLA-A24-restricted T-cell epitope, Survivin-C58, derived from a wild type survivin, and compared their immunoge...
Autores principales: | Kobayashi, Jun-ichi, Torigoe, Toshihiko, Hirohashi, Yoshihiko, Idenoue, Satomi, Miyazaki, Akihiro, Yamaguchi, Akira, Hiratsuka, Hiroyoshi, Sato, Noriyuki |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627828/ https://www.ncbi.nlm.nih.gov/pubmed/19123955 http://dx.doi.org/10.1186/1479-5876-7-1 |
Ejemplares similares
-
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer
por: Tsuruma, Tetsuhiro, et al.
Publicado: (2004) -
Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer
por: Ryan, B, et al.
Publicado: (2005) -
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA‐A24‐positive pancreatic adenocarcinoma
por: Shima, Hiroaki, et al.
Publicado: (2019) -
Survivin 2α: a novel Survivin splice variant expressed in human malignancies
por: Caldas, Hugo, et al.
Publicado: (2005) -
Potential Survival Benefit of Anti-Apoptosis Protein: Survivin-Derived Peptide Vaccine with and without Interferon Alpha Therapy for Patients with Advanced or Recurrent Urothelial Cancer—Results from Phase I Clinical Trials
por: Tanaka, Toshiaki, et al.
Publicado: (2013)